Pralnacasan inhibits proinflammatory cytokines IL-18, IL-1β , and IFN-γ. Pralnacasan is an effective, non-peptide, and orally active interleukin-1β converting enzyme inhibitor (Ki: 1.4 nM). Pralnacasan has the potential for osteoarthritis and rheumatoid a
Triptoquinone B is a novel interleukin-1 inhibitor, shows extremely potent inhibitory activities against interleukin-lα and β releases for human peripheral mononticlear cells, it shows the significant immunosuppressive activity.